MannKind Corporation

MannKind Corporation is a biopharmaceutical company focused on innovative drug delivery technologies, particularly inhaled therapies for chronic diseases. Founded in 1991 and headquartered in Danbury, Connecticut, MannKind specializes in treatments for cardiometabolic diseases, orphan lung diseases, pulmonary hypertension, and fluid overload in heart and chronic kidney disease. The company utilizes its proprietary Technosphere® platform for pulmonary drug delivery. Key marketed products include Afrezza® (inhaled insulin for diabetes), V-Go® (all-in-one insulin delivery patch), FUROSCIX® (furosemide injection for fluid overload), and Tyvaso DPI® (treprostinil inhalation powder for pulmonary hypertension, utilizing Technosphere technology under partnership with United Therapeutics). MannKind is committed to enhancing patient outcomes through transformative therapies and ongoing clinical development across endocrine and orphan lung disease indications.